US 12,403,154 B2
Administration of sting agonist and checkpoint inhibitors
Eric Scott Lightcap, Somerville, MA (US); and Yosuke Sato, Osaka (JP)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Appl. No. 17/625,422
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
PCT Filed Jul. 9, 2020, PCT No. PCT/IB2020/056440
§ 371(c)(1), (2) Date Jan. 7, 2022,
PCT Pub. No. WO2021/005541, PCT Pub. Date Jan. 14, 2021.
Claims priority of provisional application 62/994,911, filed on Mar. 26, 2020.
Claims priority of provisional application 62/944,650, filed on Dec. 6, 2019.
Claims priority of provisional application 62/872,039, filed on Jul. 9, 2019.
Prior Publication US 2022/0257630 A1, Aug. 18, 2022
Int. Cl. A61K 31/7084 (2006.01); A61K 35/00 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/7084 (2013.01) [A61K 35/00 (2013.01); A61K 45/06 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A method of treating a patient having cancer, comprising:
administering to a patient in need of said treating Compound No. 14, having the following structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and
a checkpoint inhibitor, wherein the checkpoint inhibitor is an anti-PD1 antibody or an anti-PD-L1 antibody, and wherein administering Compound No. 14 and the checkpoint inhibitor provides a synergistic effect.